These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 20169039)

  • 21. Clinical effects of selective estrogen receptor modulators on vulvar and vaginal atrophy.
    Pinkerton JV; Stanczyk FZ
    Menopause; 2014 Mar; 21(3):309-19. PubMed ID: 23777900
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Next generation selective estrogen receptor modulators].
    Chaki O
    Clin Calcium; 2006 Jan; 16(1):145-52. PubMed ID: 16397365
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lasofoxifene for postmenopausal women with osteoporosis.
    Silva-Fernández L; Andreu JL
    N Engl J Med; 2010 Jun; 362(23):2228; author reply 2228-9. PubMed ID: 20568310
    [No Abstract]   [Full Text] [Related]  

  • 24. [Third generation selective estrogen receptor modulators: benefits beyond bone. II, endometrial action].
    Calaf Alsina J; Coronado Martín PJ
    Med Clin (Barc); 2013 Mar; 140(6):266-71. PubMed ID: 23276611
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lasofoxifene in postmenopausal women with osteoporosis.
    Cummings SR; Ensrud K; Delmas PD; LaCroix AZ; Vukicevic S; Reid DM; Goldstein S; Sriram U; Lee A; Thompson J; Armstrong RA; Thompson DD; Powles T; Zanchetta J; Kendler D; Neven P; Eastell R;
    N Engl J Med; 2010 Feb; 362(8):686-96. PubMed ID: 20181970
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis.
    Lewiecki EM
    Ther Clin Risk Manag; 2009; 5():817-27. PubMed ID: 19898646
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lasofoxifene for postmenopausal women with osteoporosis.
    Malozowski S
    N Engl J Med; 2010 Jun; 362(23):2227; author reply 2228-9. PubMed ID: 20558377
    [No Abstract]   [Full Text] [Related]  

  • 28. Lasofoxifene: Evidence of its therapeutic value in osteoporosis.
    Gennari L; Merlotti D; De Paola V; Nuti R
    Core Evid; 2010 Jun; 4():113-29. PubMed ID: 20694069
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The gynecologic effects of lasofoxifene, an estrogen agonist/antagonist, in postmenopausal women.
    Archer DF
    Menopause; 2011 Jan; 18(1):6-7. PubMed ID: 21173718
    [No Abstract]   [Full Text] [Related]  

  • 30. Benefit-risk assessment of raloxifene in postmenopausal osteoporosis.
    Cranney A; Adachi JD
    Drug Saf; 2005; 28(8):721-30. PubMed ID: 16048357
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lasofoxifene: a third-generation selective estrogen receptor modulator for the prevention and treatment of osteoporosis.
    Gennari L; Merlotti D; Martini G; Nuti R
    Expert Opin Investig Drugs; 2006 Sep; 15(9):1091-103. PubMed ID: 16916275
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: Five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial.
    Ensrud K; LaCroix A; Thompson JR; Thompson DD; Eastell R; Reid DM; Vukicevic S; Cauley J; Barrett-Connor E; Armstrong R; Welty F; Cummings S
    Circulation; 2010 Oct; 122(17):1716-24. PubMed ID: 20937977
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Not all selective estrogen response modulators are created equal: update on lasofoxifene.
    Goldstein SR
    Int J Gynecol Cancer; 2006; 16 Suppl 2():504. PubMed ID: 17010058
    [No Abstract]   [Full Text] [Related]  

  • 34. Raloxifene: a review of its use in postmenopausal osteoporosis.
    Clemett D; Spencer CM
    Drugs; 2000 Aug; 60(2):379-411. PubMed ID: 10983739
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New management options for osteoporosis with emphasis on SERMs.
    McClung MR
    Climacteric; 2015; 18 Suppl 2():56-61. PubMed ID: 26503459
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lasofoxifene for postmenopausal women with osteoporosis.
    Katzeff BS
    N Engl J Med; 2010 Jun; 362(23):2227-8; author reply 2228-9. PubMed ID: 20568309
    [No Abstract]   [Full Text] [Related]  

  • 37. Bazedoxifene: bazedoxifene acetate, TSE 424, TSE-424, WAY 140424.
    Drugs R D; 2008; 9(3):191-6. PubMed ID: 18457472
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging selective estrogen receptor modulators: special focus on effects on coronary heart disease in postmenopausal women.
    Vogelvang TE; van der Mooren MJ; Mijatovic V; Kenemans P
    Drugs; 2006; 66(2):191-221. PubMed ID: 16451093
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Another selective estrogen-receptor modulator for osteoporosis.
    Becker C
    N Engl J Med; 2010 Feb; 362(8):752-4. PubMed ID: 20181977
    [No Abstract]   [Full Text] [Related]  

  • 40. Not all SERMs are created equal.
    Goldstein SR
    Menopause; 2006; 13(3):325-7. PubMed ID: 16735926
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.